Back to Anti-CTLA-4 mAb

Anti-CTLA-4 mAb

Showing 6 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Minniti et al.	2019	Retrospective	Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity	10.1186/s40425-019-0588-y	—	45	54.0	Melanoma	oligometastatic, metastatic	Anti-CTLA-4 mAb	Ipilimumab	—	Missing	intra-cranial	brain	—	Missing	18	27	Missing	1	3	Missing	9	22	Treatment-rel.	—	—	11	any G3: 21 AEs	any G3: 11 pts	any G3: Diarrhoea, Nausea/Vomiting, Increased AST and/or ALT levels, Fatigue, Rash/Pruritus, Muscle weakness, Headache, Hemorrhage, Seizure, Brain necrosis	unknown
Diao et al.	2018	Retrospective	Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity	10.1007/s11060-018-2880-y	—	23	62.0	Melanoma	metastatic	Anti-CTLA-4 mAb	Ipilimumab	—	Missing	intra-cranial	brain	—	20	12	22	1	1	1	20	12	22	RT-related	1	2	—	Missing	acute G3: 1 pt, late G3: 1 pt, late G4: 1pt	Missing	—
Sundahl et al.	2018	Prospective	Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma	10.1016/j.ijrobp.2017.11.029	NCT02406183	5	63.0	Melanoma	metastatic	Anti-CTLA-4 mAb	Ipilimumab	—	5	extra-cranial	abdominal LN, liver, other	subcutaneous lesions	24	24	24	3	3	3	8	8	8	Treatment-rel.	—	—	1	any G3: 1 AE	any G3: 1 pt	any G3: diarrhea	—
Sundahl et al.	2018	Prospective	Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma	10.1016/j.ijrobp.2017.11.029	NCT02406183	1	23.0	Melanoma	metastatic	Anti-CTLA-4 mAb	Ipilimumab	—	1	extra-cranial	abdominal LN	—	30	30	30	3	3	3	10	10	10	Treatment-rel.	—	—	0	—	—	—	—
Sundahl et al.	2018	Prospective	Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma	10.1016/j.ijrobp.2017.11.029	NCT02406183	6	70.0	Melanoma	metastatic	Anti-CTLA-4 mAb	Ipilimumab	—	6	extra-cranial	thoracic LN, lung, other	soft tissue, subcutaneous lesion	36	36	36	3	3	3	12	12	12	Treatment-rel.	—	—	2	any G4: 2 AEs	any G4: 2 pts	any G4: colitis	—
Skrepnik et al.	2017	Retrospective	Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab	10.1080/2162402x.2017.1283461	—	25	68.5	Melanoma	metastatic	Anti-CTLA-4 mAb	Ipilimumab	—	58	intra-cranial	brain	—	21	16	24	1	1	1	21	16	24	Radiation necrosis	—	0	—	—	—	—	—